Bioiberica empowering the health evolution at Vitafoods Europe

Date: 10.05.2022Source: Bioiberica

Bioiberica, a global Life Science company with more than 45 years of experience in the identification and extraction of molecules of high biologic and therapeutic value for the pharmaceutical and nutraceutical industries, has announced the launch of two additions to its branded ingredients portfolio – DAOgest and Dermial for digestive health and skin & beauty respectively at this years Vitafoods Europe. The company is also marking the event by spotlighting new delivery formats for its Collavant n2 native (undenatured) type II collagen ingredient for joint health.

Said Jaume Reguant, Healthcare Director, Bioiberica: “Histamine intolerance affects an estimated 1-3% of the global population, causing them to experience allergy-like symptoms after consuming histamine rich foods. We’re calling on our industry partners to join forces with us in our goal to develop long-term health solutions that will improve lives for generations to come. With DAOgest, we’re giving manufacturers the opportunity to do just that – to create finished dosage forms that have the power to enable those suffering with this digestive condition to enjoy their favourite foods and drinks.”

Harnessing Bioiberica’s decades of scientific research and expertise in glycosaminoglycans, Dermial contains a combination of three naturally-occurring components – hyaluronic acid, glycosaminoglycans (including dermatan and chondroitin sulfate) and hydrolysed collagen. Together, they work in synergy to enable the development of cutting-edge products that nourish, hydrate and replenish the skin. Demonstrated by scientific studies, this unique composition has been shown to elicit superior results when compared to microbial fermentation origin hyaluronic acid, including increased in vitro production of type I collagen by 48%.

Concluded Reguant: “Consumers are increasingly opting for formats beyond pills, capsules and softgels – including gummies and functional products – to help them meet specific health and nutrition goals. Gummy solutions, especially, are becoming a preferred format for many. With a reported 75% growth in 2021, they now have the largest non-pill market share at 21.3%.”  For more visit bioiberica.com

David Cox / IDM

Print article (with images) Print article (without images)


Always stay up to date and sign up for our newsletter service: